Earnings call transcript: Sampo lifts 2026 outlook as Q3 growth stays strong

Sampo raised its full-year 2026 insurance revenue outlook to EUR 9.75 billion–EUR 9.85 billion from EUR 9.65 billion–EUR 9.75 billion, and its underwriting result outlook to EUR 1.60 billion–EUR 1.65 billion from EUR 1.55 billion–EUR 1.625 billion. Q3 insurance revenue rose 9%, like-for-like gross written premium growth accelerated to 6% from 5% in Q2, and solvency coverage was 175%, including the full 90% distribution accrual. Shares were up 0.63% at $9.65 pre-market; management also cited fixed-income mark-to-market losses amid higher rates and ongoing claims-inflation uncertainty.

Analysis

Sampo: strong execution, but claims luck and price discipline are the swing factors. The upgrade supports the durability of the underwriting franchise, yet the more investable signal is whether volume-led growth converts to margin after claims normalize. Favorable severe-weather and large-claim experience helped results; reserve prudence is sensible, but it does not eliminate the risk that claims inflation—particularly wages and repair costs—outpaces renewal pricing. Bundling and retention defend customer economics, while discounts mean policy growth alone is not proof of better unit profitability. Topdanmark synergies can add operating leverage, though segment cost-ratio comparisons remain noisy until integration effects wash through.

Higher rates create a two-sided earnings path: near-term fixed-income marks can weigh on reported results and solvency, while reinvestment at higher yields should support future investment income. The benefit arrives gradually and should not be treated as an immediate offset. The 2027 shift to “core” earnings is described as non-material; investors should nevertheless reconcile the new measure to cash earnings and distributions rather than assume improved performance. The third-quarter share response was modest and the shares are near their annual high, so chasing the upgrade offers less attractive asymmetry. Treat third-party fair-value labels as non-independent signals, not a valuation conclusion.

Catalysts: Over the next 1–3 months, monitor claims trends and the November 17 strategy update for targets and evidence of continued UK pricing improvement. Over 6–18 months, test whether organic growth and integration savings persist through a less benign claims cycle. Thesis weakens if the combined ratio deteriorates, guidance is cut, or solvency falls materially after distributions.

Key Decisions for Investors

• No fresh outright long at the current elevated range: the operating update is constructive, but favorable claims experience and limited near-term upside after the rally leave an unappealing chase. Reassess on a pullback or after the strategy update.
• For existing holders, retain exposure only while underwriting margins hold through claims normalization; use combined-ratio deterioration, a guidance reduction, or a material solvency decline as explicit review triggers.
• Set an alert for the November 17 investor update: require quantified evidence on UK renewal pricing, Topdanmark cost savings, and next-period capital returns before adding. Verify reported-versus-underlying claims costs and solvency sensitivity to rates; the supplied data do not establish a suitable entry price or valuation discount.